Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auricular Point Stimulation Plus Dexamethasone for CINV in Pancreatic Cancer
NCT07716228Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0 at 5 days. Started Dec 2025; status: recruiting.
02
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07716228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716228.